Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

NEW YORK and CLEVELAND, Jan. 19, 2017 (GLOBE NEWSWIRE) —

  • ABO-101, Abeona‚Äôs third AAV gene therapy program to receive EMA Orphan Designation
  • Clinical trials anticipated to begin enrolling in second